Evident Vascular Closes Series B Financing

<p><strong>SAN JOSE<&sol;strong> &&num;8212&semi; Evident Vascular&comma; Inc&period;&comma; a medical technology company developing a best-in-class intravascular ultrasound &lpar;IVUS&rpar; platform powered by artificial intelligence&comma; has closed its Series B financing with new investors Shangbay Capital and two undisclosed multinational strategics joining founding investor Vensana Capital&period; The funding will accelerate the development of the Company’s advanced IVUS technology designed to enhance vascular imaging and patient outcomes and support 510&lpar;k&rpar; FDA clearance ahead of U&period;S&period; market launch&period; The amount the company received was not revealed&period;<&sol;p>&NewLine;<p>&OpenCurlyDoubleQuote;We are proud to continue supporting Evident Vascular&comma; which is at the forefront of innovation in intravascular imaging that has become the standard of care in peripheral vascular and complex coronary interventions&comma;” <b>said Cynthia Yee&comma; Partner at Vensana Capital&period;<&sol;b> &OpenCurlyDoubleQuote;Evident’s next generation IVUS platform represents a transformative step forward in vascular care&comma; offering clinicians powerful tools to enhance diagnosis and guide treatment consistent with clinical evidence and today’s medical guidelines<sup>1<&sol;sup>&period;”<&sol;p>&NewLine;<p>Evident Vascular’s vision is to transform vascular imaging through innovations that expand the adoption of IVUS by increasing its utility and accessibility in clinical practice&period; The Company’s commitment to innovation is driven by a team of industry experts&comma; whose leadership further bolsters Evident’s trajectory toward success&period;<&sol;p>&NewLine;<p>&OpenCurlyDoubleQuote;This significant investment underscores our investors&&num;8217&semi; confidence in Evident Vascular’s mission and technology while highlighting the vital role of intravascular imaging in optimizing patient outcomes&comma; clinical decision-making and procedural success&comma;” <b>stated Howard Rosen&comma; CEO and co-founder of Evident Vascular&period;<&sol;b> &OpenCurlyDoubleQuote;We will accelerate our progress toward FDA clearance and further the development of our AI-powered IVUS solution&comma; which aims to set a new standard in vascular image guided therapy&period;”<&sol;p>&NewLine;